<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; any</title>
	<atom:link href="http://www.tapanray.in/tag/any/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Seeing ghosts where there aren&#8217;t any</title>
		<link>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=seeing-ghosts-where-there-arent-any</link>
		<comments>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/#comments</comments>
		<pubDate>Mon, 10 Oct 2011 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[aren't]]></category>
		<category><![CDATA[attractive]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[ghosts]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seeing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[viebachar]]></category>
		<category><![CDATA[where]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=190</guid>
		<description><![CDATA[Seeing ghosts almost everywhere in the Indian pharmaceutical industry, especially where there aren&#8217;t any, has indeed become quite common nowadays, across the spectrum of stakeholders. The ‘ghosts’ could well reside in ‘100% Foreign Direct Investments (FDI) through automatic route in &#8230; <a href="http://www.tapanray.in/seeing-ghosts-where-there-arent-any/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will Global Pharma Majors be successful in their foray into highly competitive generics pharma business offering no (patent) protection of any kind?</title>
		<link>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind</link>
		<comments>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/#comments</comments>
		<pubDate>Mon, 05 Jul 2010 01:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[foray]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[highly]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[kind]]></category>
		<category><![CDATA[majors]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[offering]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[successful]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=406</guid>
		<description><![CDATA[As reported by IMS Health, emerging markets will register a growth rate of 14% to 17% by 2014, when the developed markets will be growing by 3% to 6% during the same period. It is forecasted that the global pharmaceutical &#8230; <a href="http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is the revised Mashelkar Committee Report a ‘please all’ report, without taking any chance to &#8216;rock the boat&#8217;?</title>
		<link>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat</link>
		<comments>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/#comments</comments>
		<pubDate>Mon, 15 Jun 2009 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[boat]]></category>
		<category><![CDATA[chance]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[incremental innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[please]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[rock]]></category>
		<category><![CDATA[Taking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=860</guid>
		<description><![CDATA[After repeated request and persuasion by the Government of India (GoI) in general and the Department of Industrial Policy and Promotion (DIPP) in particular ‘The Mashelkar Committee’re-submitted its reports to the GoI under the following terms of references: Terms of &#8230; <a href="http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
